Outcomes of Patients with Melioidosis Treated with Meropenem

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1763-1765

  Cheng, Allen C ^a,b   Fisher, Dale A ^b,c   Anstey, Nicholas M ^a,b,c   Stephens, Dianne P ^b,c   Jacups, Susan P ^a,b   Currie, Bart J ^a,b,c  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CHLORAMPHENICOL; COTRIMOXAZOLE; DOXYCYCLINE; IMIPENEM; MEROPENEM;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; BURKHOLDERIA PSEUDOMALLEI; CHILD; DISEASE SEVERITY; DRUG FEVER; ENDEMIC DISEASE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MELIOIDOSIS; MORTALITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RASH; SEIZURE; SEPSIS; SOUTHEAST ASIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CEFTAZIDIME; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MELIOIDOSIS; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; THIENAMYCINS; TREATMENT OUTCOME;

EID: 2142768795     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1763-1765.2004     Document Type: Article

References (23)

1. American College of Chest Physicians/Society of Critical Care Medicine. 1992. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20:864-874.
2. Annane, D., V. Sebille, C. Charpentier, P. E. Bollaert, B. Francois, J. M. Korach, G. Capellier, Y. Cohen, E. Azoulay, G. Troche, P. Chaumet-Riffaut, and E. Bellissant. 2002. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862-871.
3. Brook, A. D., T. S. Ahrens, R. Schaiff, D. Prentice, G. Sherman, W. Shannon, and M. H. Kollef. 1999. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit. Care Med. 27:2609-2615.
4. Cheng, A. C., D. P. Stephens, N. M. Anstey, and B. J. Currie. 2004. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin. Infect. Dis. 38:32-37.
5. Currie, B. J., D. A. Fisher, D. M. Howard, J. N. Burrow, D. Lo, S. Selva-Nayagam, N. M. Anstey, S. E. Huffam, P. L. Snelling, P. J. Marks, D. P. Stephens, G. D. Lum, S. P. Jacups, and V. L. Krause. 2000. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin. Infect. Dis. 31:981-986.
6. Giles, L. J., A. C. Jennings, A. H. Thomson, G. Creed, R. J. Beale, and A. McLuckie. 2000. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit. Care Med. 28:632-637.
7. Guard, R. W., F. A. Khafagi, M. C. Brigden, and L. R. Ashdown. 1984. Melioidosis in Far North Queensland. A clinical and epidemiological review of twenty cases. Am. J. Trop. Med. Hyg. 33:467-473.
8. Hsueh, P. R., L. J. Teng, L. N. Lee, C. J. Yu, P. C. Yang, S. W. Ho, and K. T. Luh. 2001. Melioidosis: an emerging infection in Taiwan? Emerg. Infect. Dis. 7:428-433.
9. Inglis, T. J., C. L. Golledge, A. Clair, and J. Harvey. 2001. Case report: recovery from persistent septicemic melioidosis. Am. J. Trop. Med. Hyg. 65:76-82.
10. Jenney, A. W., G. Lum, D. A. Fisher, and B. J. Currie. 2001. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int. J. Antimicrob. Agents 17: 109-113.
11. Puthucheary, S. D., N. Parasakthi, and M. K. Lee. 1992. Septicaemic melioidosis: a review of 50 cases from Malaysia. Trans. R. Soc. Trop. Med. Hyg. 86:683-685.
12. Rivers, E., B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, B. Knoblich, E. Peterson, and M. Tomlanovich. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345:1368-1377.
13. Schulin, T., and I. Steinmetz. 2001. Chronic melioidosis in a patient with cystic fibrosis. J. Clin. Microbiol. 39:1676-1677.
14. Simpson, A. J., S. M. Opal, B. J. Angus, J. M. Prins, J. E. Palardy, N. A. Parejo, W. Chaowagul, and N. J. White. 2000. Differential antibiotic-induced endotoxin release in severe melioidosis. J. Infect. Dis. 181:1014-1019.
15. Simpson, A. J., Y. Suputtamongkol, M. D. Smith, B. J. Angus, A. Rajanu-wong, V. Wuthiekanun, P. A. Howe, A. L. Walsh, W. Chaowagul, and N. J. White. 1999. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis. 29:381-387.
16. Smith, M. D., V. Wuthiekanun, A. L. Walsh, and N. J. White. 1996. In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. J. Antimicrob. Chemother. 37:611-615.
17. Smith, M. D., V. Wuthiekanun, A. L. Walsh, and N. J. White. 1994. Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies. J. Antimicrob. Chemother. 33:145-149.
18. Stephens, D. P., D. A. Fisher, and B. J. Currie. 2002. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern. Med. J. 32:143-148.
19. Walsh, A. L., M. D. Smith, V. Wuthiekanun, and N. J. White. 1995. Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: an evaluation of current treatment. Antimicrob. Agents Chemother. 39:2356-2358.
20. White, N. J. 2003. Melioidosis. Lancet 361:1715-1722.
21. White, N. J., D. A. Dance, W. Chaowagul, Y. Wattanagoon, V. Wuthiekanun, and N. Pitakwatchara. 1989. Halving of mortality of severe melioidosis by ceftazidime. Lancet ii:697-701.
22. Writing Group. 2003. Therapeutic guidelines: antibiotic, 12th ed. Therapeutic Guidelines Ltd., North Melbourne, Australia.
23. Yamamoto, T., P. Naigowit, S. Dejsirilert, D. Chiewsilp, E. Kondo, T. Yokota, and K. Kanai. 1990. In vitro susceptibilities of Pseudomonas pseudomallei to 27 antimicrobial agents. Antimicrob. Agents Chemother. 34:2027-2029.